Relationships between mitochondria and neuroinflammation: Implications for alzheimer’s disease

Current Topics in Medicinal Chemistry

Volumn 16, Issue 8, 2016, Pages 849-857

  Wilkins, Heather M ^a,b   Swerdlow, Russell H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Alzheimer s disease; Bioenergetics; Damage associated molecular pattern; Inflammation; Mitochondria

Indexed keywords

ADENYLATE KINASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; CYTOCHROME C OXIDASE; EOTAXIN; GLUCOSE TRANSPORTER 3; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KETONE BODY; MESSENGER RNA; MITOCHONDRIAL TRANSCRIPTION FACTOR A; MONOCARBOXYLATE TRANSPORTER; OXALOACETIC ACID; OXOGLUTARATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; MITOCHONDRIAL DNA;

ALZHEIMER DISEASE; BIOENERGY; CALORIC RESTRICTION; CHRONIC INFLAMMATION; DIETARY INTAKE; EXERCISE; GLUCOSE UTILIZATION; GLYCOLYSIS; HEART STROKE VOLUME; HUMAN; INSULIN RESISTANCE; KETOGENIC DIET; MICROARRAY ANALYSIS; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; REVIEW; DIET THERAPY; ENERGY METABOLISM; GENETICS; INFLAMMATION; METABOLISM; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; DNA, MITOCHONDRIAL; ENERGY METABOLISM; EXERCISE; HUMANS; INFLAMMATION; KETONE BODIES; MITOCHONDRIA; NERVOUS SYSTEM DISEASES; OXALOACETIC ACID;

EID: 84973636419     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150827095102     Document Type: Review

References (81)

1. Bosetti, F.; Brizzi, F.; Barogi, S.; Mancuso, M.; Siciliano, G.; Tendi, E.A.; Murri, L.; Rapoport, S.I.; Solaini, G., Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging, 2002, 23, (3), 371-376.
2. Cardoso, S.M.; Santana, I.; Swerdlow, R.H.; Oliveira, C.R., Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem., 2004, 89, (6), 1417-1426.
3. Khan, S.M.; Cassarino, D.S.; Abramova, N.N.; Keeney, P.M.; Borland, M.K.; Trimmer, P.A.; Krebs, C.T.; Bennett, J.C.; Parks, J.K.; Swerdlow, R.H.; Parker, W.D., Jr.; Bennett, J.P., Jr., Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol., 2000, 48, (2), 148-155.
4. Maurer, I.; Zierz, S.; Moller, H.J., A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging, 2000, 21, (3), 455-462.
5. Onyango, I.G.; Bennett, J.P., Jr.; Tuttle, J.B., Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol. Dis., 2005, 19, (1-2), 312-322.
6. Parker, W.D., Jr.; Filley, C.M.; Parks, J.K., Cytochrome oxidase deficiency in Alzheimer's disease. Neurology, 1990, 40, (8), 1302-1303.
7. Silva, D.F.; Selfridge, J.E.; Lu, J.; E, L.; Roy, N.; Hutfles, L.; Burns, J.M.; Michaelis, E.K.; Yan, S.; Cardoso, S.M.; Swerdlow, R.H., Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum. Mol. Genet., 2013, 22, (19), 3931-3946.
8. Swerdlow, R.H., Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease. Antioxid. Redox Signal., 2012, 16, (12), 1434-1455.
9. Swerdlow, R.H., Mitochondrial Medicine and the Neurodegenerative Mitochondriopathies. Pharmaceuticals, 2009, 2, (3), 150-167.
10. Trimmer, P.A.; Keeney, P.M.; Borland, M.K.; Simon, F.A.; Almeida, J.; Swerdlow, R.H.; Parks, J.P.; Parker, W.D., Jr.; Bennett, J.P., Jr., Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol. Dis., 2004, 15, (1), 29-39.
11. Wilkins, H.M.; Carl, S.M.; Greenlief, A.C.; Festoff, B.W.; Swerdlow, R.H., Bioenergetic dysfunction and inflammation in Alzheimer's disease: a possible connection. Front. Aging Neurosci., 2014, 6, 311.
12. Wilkins, H.M.; Carl, S.M.; Swerdlow, R.H., Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies. Redox Biol., 2014, 2C, 619-631.
13. Di Filippo, M.; Chiasserini, D.; Tozzi, A.; Picconi, B.; Calabresi, P., Mitochondria and the link between neuroinflammation and neurodegeneration. J. Alzheimer's Dis.: JAD, 2010, 20 Suppl 2, S369-379.
14. Brown, G.C., Nitric oxide inhibition of cytochrome oxidase and mitochondrial respiration: implications for inflammatory, neurodegenerative and ischaemic pathologies. Mol. Cell. Biochem., 1997, 174, (1-2), 189-192.
15. Zhou, R.; Yazdi, A.S.; Menu, P.; Tschopp, J., A role for mitochondria in NLRP3 inflammasome activation. Nature, 2011, 469, (7329), 221-225.
16. Akiyama, H., Inflammatory response in Alzheimer's disease. The Tohoku journal of experimental medicine, 1994, 174, (3), 295-303.
17. Akiyama, H.; Arai, T.; Kondo, H.; Tanno, E.; Haga, C.; Ikeda, K., Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Associat. Disord., 2000, 14 Suppl 1, S47-53.
18. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T., Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, (3), 383-421.
19. Cagnin, A.; Brooks, D.J.; Kennedy, A.M.; Gunn, R.N.; Myers, R.; Turkheimer, F.E.; Jones, T.; Banati, R.B., In-vivo measurement of activated microglia in dementia. Lancet, 2001, 358, (9280), 461-467.
20. Versijpt, J.J.; Dumont, F.; Van Laere, K.J.; Decoo, D.; Santens, P.; Audenaert, K.; Achten, E.; Slegers, G.; Dierckx, R.A.; Korf, J., Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur. Neurol., 2003, 50, (1), 39-47.
21. Cartier, L.; Hartley, O.; Dubois-Dauphin, M.; Krause, K.H., Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res. Brain Res. Rev., 2005, 48, (1), 16-42.
22. Swardfager, W.; Lanctot, K.; Rothenburg, L.; Wong, A.; Cappell, J.; Herrmann, N., A meta-analysis of cytokines in Alzheimer's disease. Biolog. Psychiatr., 2010, 68, (10), 930-941.
23. Wilkins, H.M.; Carl, S.M.; Weber, S.G.; Ramanujan, S.A.; Festoff, B.W.; Linseman, D.A.; Swerdlow, R.H., Mitochondrial Lysates Induce Inflammation and Alzheimer's Disease-Relevant Changes in Microglial and Neuronal Cells. J. Alzheimer's Dis.: JAD, 2014.
24. Mathew, A.; Lindsley, T.A.; Sheridan, A.; Bhoiwala, D.L.; Hushmendy, S.F.; Yager, E.J.; Ruggiero, E.A.; Crawford, D.R., Degraded mitochondrial DNA is a newly identified subtype of the damage associated molecular pattern (DAMP) family and possible trigger of neurodegeneration. J. Alzheimer's Dis.: JAD, 2012, 30, (3), 617-627.
25. Crouser, E.D.; Shao, G.; Julian, M.W.; Macre, J.E.; Shadel, G.S.; Tridandapani, S.; Huang, Q.; Wewers, M.D., Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors. Critical care med., 2009, 37, (6), 2000-2009.
26. Julian, M.W.; Shao, G.; Bao, S.; Knoell, D.L.; Papenfuss, T.L.; VanGundy, Z.C.; Crouser, E.D., Mitochondrial transcription factor A serves as a danger signal by augmenting plasmacytoid dendritic cell responses to DNA. J. Immunol., 2012, 189, (1), 433-443.
27. Abramova, N.E.; Davies, K.J.; Crawford, D.R., Polynucleotide degradation during early stage response to oxidative stress is specific to mitochondria. Free Rad. Biol. Med., 2000, 28, (2), 281-288.
28. Savage, C.D.; Lopez-Castejon, G.; Denes, A.; Brough, D., NLRP3-Inflammasome Activating DAMPs Stimulate an Inflammatory Response in Glia in the Absence of Priming Which Contributes to Brain Inflammation after Injury. Front. Immunol., 2012, 3, 288.
29. Little, J.P.; Simtchouk, S.; Schindler, S.M.; Villanueva, E.B.; Gill, N.E.; Walker, D.G.; Wolthers, K.R.; Klegeris, A., Mitochondrial transcription factor A (Tfam) is a pro-inflammatory extracellular signaling molecule recognized by brain microglia. Mol. Cell. Neurosci., 2014, 60, 88-96.
30. Davis, C.H.; Kim, K.Y.; Bushong, E.A.; Mills, E.A.; Boassa, D.; Shih, T.; Kinebuchi, M.; Phan, S.; Zhou, Y.; Bihlmeyer, N.A.; Nguyen, J.V.; Jin, Y.; Ellisman, M.H.; Marsh-Armstrong, N., Transcellular degradation of axonal mitochondria. Proc. Natl. Acad. Sci. USA, 2014, 111, (26), 9633-9638.
31. Mosconi, L.; Mistur, R.; Switalski, R.; Tsui, W.H.; Glodzik, L.; Li, Y.; Pirraglia, E.; De Santi, S.; Reisberg, B.; Wisniewski, T.; de Leon, M.J., FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imag., 2009, 36, (5), 811-822.
32. Edland, S.D.; Silverman, J.M.; Peskind, E.R.; Tsuang, D.; Wijsman, E.; Morris, J.C., Increased risk of dementia in mothers of Alzheimer's disease cases: evidence for maternal inheritance. Neurology, 1996, 47, (1), 254-256.
33. Honea, R.A.; Vidoni, E.D.; Swerdlow, R.H.; Burns, J.M.; Alzheimer's Disease Neuroimaging, I., Maternal family history is associated with Alzheimer's disease biomarkers. J. Alzheimer's Dis.: JAD, 2012, 31, (3), 659-668.
34. Mosconi, L.; Brys, M.; Switalski, R.; Mistur, R.; Glodzik, L.; Pirraglia, E.; Tsui, W.; De Santi, S.; de Leon, M.J., Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. USA, 2007, 104, (48), 19067-19072.
35. Swerdlow, R.H.; Burns, J.M.; Khan, S.M., The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochimica et biophysica acta, 2014, 1842, (8), 1219-1231.
36. Swerdlow, R.H.; Khan, S.M., A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypoth., 2004, 63, (1), 8-20.
37. Soares, H.D.; Potter, W.Z.; Pickering, E.; Kuhn, M.; Immermann, F.W.; Shera, D.M.; Ferm, M.; Dean, R.A.; Simon, A.J.; Swenson, F.; Siuciak, J.A.; Kaplow, J.; Thambisetty, M.; Zagouras, P.; Koroshetz, W.J.; Wan, H.I.; Trojanowski, J.Q.; Shaw, L.M., Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol., 2012, 69, (10), 1310-1317.
38. Faria, M.C.; Goncalves, G.S.; Rocha, N.P.; Moraes, E.N.; Bicalho, M.A.; Gualberto Cintra, M.T.; Jardim de Paula, J.; Jose Ravic de Miranda, L.F.; Clayton de Souza Ferreira, A.; Teixeira, A.L.; Gomes, K.B.; Carvalho, M.; Sousa, L.P., Increased plasma levels of BDNF and inflammatory markers in Alzheimer's disease. J. Psychiatr. Res., 2014, 53, 166-172.
39. Leung, R.; Proitsi, P.; Simmons, A.; Lunnon, K.; Guntert, A.; Kronenberg, D.; Pritchard, M.; Tsolaki, M.; Mecocci, P.; Kloszewska, I.; Vellas, B.; Soininen, H.; Wahlund, L.O.; Lovestone, S., Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One, 2013, 8, (6), e64971.
40. Zhang, R.; Miller, R.G.; Madison, C.; Jin, X.; Honrada, R.; Harris, W.; Katz, J.; Forshew, D.A.; McGrath, M.S., Systemic immune system alterations in early stages of Alzheimer's disease. J. Neuroimmunol., 2013, 256, (1-2), 38-42.
41. Alsadany, M.A.; Shehata, H.H.; Mohamad, M.I.; Mahfouz, R.G., Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am. J. Alzheimer's Dis. Other Dement., 2013, 28, (1), 54-61.
42. Lee, K.S.; Chung, J.H.; Choi, T.K.; Suh, S.Y.; Oh, B.H.; Hong, C.H., Peripheral cytokines and chemokines in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2009, 28, (4), 281-287.
43. Luft, R., The development of mitochondrial medicine. Proc. Natl. Acad. Sci. USA,1994, 91, (19), 8731-8738.
44. Swerdlow, R.H., Bioenergetic medicine. Br. J. Pharmacol., 2014, 171, (8), 1854-1869.
45. Swerdlow, R.H., Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases. Curr. Pharm. Des., 2011, 17, (31), 3356-3373.
46. Wilkins, H.M.; Harris, J.L.; Carl, S.M.; E, L.; Lu, J.; Eva Selfridge, J.; Roy, N.; Hutfles, L.; Koppel, S.; Morris, J.; Burns, J.M.; Michaelis, M.L.; Michaelis, E.K.; Brooks, W.M.; Swerdlow, R.H., Oxaloacetate activates brain mitochondrial biogenesis, enhances the insulin pathway, reduces inflammation and stimulates neurogenesis. Hum. Mol. Genet., 2014, 23, (24), 6528-6541.
47. Lin, S.J.; Guarente, L., Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell. Biol., 2003, 15, (2), 241-246.
48. Hakimi, P.; Yang, J.; Casadesus, G.; Massillon, D.; Tolentino-Silva, F.; Nye, C.K.; Cabrera, M.E.; Hagen, D.R.; Utter, C.B.; Baghdy, Y.; Johnson, D.H.; Wilson, D.L.; Kirwan, J.P.; Kalhan, S.C.; Hanson, R.W., Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J. Biol. Chem., 2007, 282, (45), 32844-32855.
49. Williams, D.S.; Cash, A.; Hamadani, L.; Diemer, T., Oxaloacetate supplementation increases lifespan in Caenorhabditis elegans through an AMPK/FOXO-dependent pathway. Aging Cell, 2009, 8, (6), 765-768.
50. Yamamoto, H.A.; Mohanan, P.V. Effect of alpha-ketoglutarate and oxaloacetate on brain mitochondrial DNA damage and seizures induced by kainic acid in mice. Toxicol. Lett, 2003, 143, (2), 115-122.
51. Campos, F.; Sobrino, T.; Ramos-Cabrer, P.; Castillo, J. Oxaloacetate: a novel neuroprotective for acute ischemic stroke. Int. J. Biochem. Cell. Biol., 2012, 44, (2), 262-265.
52. Ruban, A.; Berkutzki, T.; Cooper, I.; Mohar, B.; Teichberg, V.I. Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas. Investigat. N. Drugs, 2012.
53. Zlotnik, A.; Sinelnikov, I.; Gruenbaum, B.F.; Gruenbaum, S.E.; Dubilet, M.; Dubilet, E.; Leibowitz, A.; Ohayon, S.; Regev, A.; Boyko, M.; Shapira, Y.; Teichberg, V.I. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology, 2012, 116, (1), 73-83.
54. Yoshikawa, K. Studies on the anti-diabetic effect of sodium oxaloacetate. Tohoku J. Exp. Med., 1968, 96, (2), 127-141.
55. Villeda, S.A.; Luo, J.; Mosher, K.I.; Zou, B.; Britschgi, M.; Bieri, G.; Stan, T.M.; Fainberg, N.; Ding, Z.; Eggel, A.; Lucin, K.M.; Czirr, E.; Park, J.S.; Couillard-Despres, S.; Aigner, L.; Li, G.; Peskind, E.R.; Kaye, J.A.; Quinn, J.F.; Galasko, D.R.; Xie, X.S.; Rando, T.A.; Wyss-Coray, T. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 2011, 477, (7362), 90-94.
56. Lu, J.; E, L.; Wang, W.; Frontera, J.; Zhu, H.; Wang, W.T.; Lee, P.; Choi, I.Y.; Brooks, W.M.; Burns, J.M.; Aires, D.; Swerdlow, R.H. Alternate day fasting impacts the brain insulin-signaling pathway of young adult male C57BL/6 mice. J. Neurochem., 2011, 117, (1), 154-163.
57. Huttenlocher, P.R. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy. Pediatr. Res., 1976, 10, (5), 536-540.
58. Neal, E.G.; Chaffe, H.; Schwartz, R.H.; Lawson, M.S.; Edwards, N.; Fitzsimmons, G.; Whitney, A.; Cross, J.H. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol., 2008, 7, (6), 500-506.
59. Krikorian, R.; Shidler, M.D.; Dangelo, K.; Couch, S.C.; Benoit, S.C.; Clegg, D.J. Dietary ketosis enhances memory in mild cognitive impairment. Neurobiol. Aging, 2012, 33, (2), 425 e419-427.
60. Reger, M.A.; Henderson, S.T.; Hale, C.; Cholerton, B.; Baker, L.D.; Watson, G.S.; Hyde, K.; Chapman, D.; Craft, S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging, 2004, 25, (3), 311-314.
61. Henderson, S.T.; Vogel, J.L.; Barr, L.J.; Garvin, F.; Jones, J.J.; Costantini, L.C. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.), 2009, 6, 31.
62. Cheng, C.M.; Kelley, B.; Wang, J.; Strauss, D.; Eagles, D.A.; Bondy, C.A. A ketogenic diet increases brain insulin-like growth factor receptor and glucose transporter gene expression. Endocrinology, 2003, 144, (6), 2676-2682.
63. Bough, K.J.; Wetherington, J.; Hassel, B.; Pare, J.F.; Gawryluk, J.W.; Greene, J.G.; Shaw, R.; Smith, Y.; Geiger, J.D.; Dingledine, R.J. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann. Neurol., 2006, 60, (2), 223-235.
64. Selfridge, J.E.; Wilkins, H.M.; E, L.; Carl, S.M.; Koppel, S.; Funk, E.; Fields, T.; Lu, J.; Tang, E.P.; Slawson, C.; Wang, W.; Zhu, H.; Swerdlow, R.H. Effect of one month duration ketogenic and nonketogenic high fat diets on mouse brain bioenergetic infrastructure. J. Bioenerget. Biomembr., 2014.
65. Hood, D.A. Mechanisms of exercise-induced mitochondrial biogenesis in skeletal muscle. Appl. Physiol. Nutr. Metab., 2009, 34, (3), 465-472.
66. Holloszy, J.O. Adaptation of skeletal muscle to endurance exercise. Med. Sci. Sports, 1975, 7, (3), 155-164.
67. Ristow, M.; Zarse, K.; Oberbach, A.; Kloting, N.; Birringer, M.; Kiehntopf, M.; Stumvoll, M.; Kahn, C.R.; Bluher, M. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA, 2009, 106, (21), 8665-8670.
68. Gomez-Cabrera, M.C.; Domenech, E.; Romagnoli, M.; Arduini, A.; Borras, C.; Pallardo, F.V.; Sastre, J.; Vina, J. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Am. J. Clin. Nutr., 2008, 87, (1), 142-149.
69. Koltai, E.; Szabo, Z.; Atalay, M.; Boldogh, I.; Naito, H.; Goto, S.; Nyakas, C.; Radak, Z. Exercise alters SIRT1, SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech. Ageing Dev., 2010, 131, (1), 21-28.
70. E, L.; Lu, J.; Burns, J.M.; Swerdlow, R.H. Effect of exercise on mouse liver and brain bioenergetic infrastructures. Exper. Physiol., 2013, 98, (1), 207-219.
71. E, L.; Lu, J.; Selfridge, J.E.; Burns, J.M.; Swerdlow, R.H. Lactate administration reproduces specific brain and liver exercise-related changes. J. Neurochem., 2013, 127, (1), 91-100.
72. Cotman, C.W.; Berchtold, N.C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci, 2002, 25, (6), 295-301.
73. van Praag, H.; Shubert, T.; Zhao, C.; Gage, F.H. Exercise enhances learning and hippocampal neurogenesis in aged mice. J. Neurosci., 2005, 25, (38), 8680-8685.
74. Boveris, A.; Navarro, A. Systemic and mitochondrial adaptive responses to moderate exercise in rodents. Free Rad. Biol. Med., 2008, 44, (2), 224-229.
75. Navarro, A.; Gomez, C.; Lopez-Cepero, J.M.; Boveris, A. Beneficial effects of moderate exercise on mice aging: survival, behavior, oxidative stress, and mitochondrial electron transfer. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 286, (3), R505-511.
76. Steiner, J.L.; Murphy, E.A.; McClellan, J.L.; Carmichael, M.D.; Davis, J.M. Exercise training increases mitochondrial biogenesis in the brain. J. Appl. Physiol., 2011, 111, (4), 1066-1071.
77. E, L.; Burns, J.M.; Swerdlow, R.H. Effect of high-intensity exercise on aged mouse brain mitochondria, neurogenesis, and inflammation. Neurobiol. Aging, 2014, 35, (11), 2574-2583.
78. Magistretti, P.J. Neuron-glia metabolic coupling and plasticity. J. Exp. Biol., 2006, 209, (Pt 12), 2304-2311.
79. Pellerin, L.; Magistretti, P.J. Neuroenergetics: calling upon astrocytes to satisfy hungry neurons. Neuroscientist, 2004, 10, (1), 53-62.
80. Suzuki, A.; Stern, S.A.; Bozdagi, O.; Huntley, G.W.; Walker, R.H.; Magistretti, P.J.; Alberini, C.M. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell, 2011, 144, (5), 810-823.
81. Wyss, M.T.; Jolivet, R.; Buck, A.; Magistretti, P.J.; Weber, B. In vivo evidence for lactate as a neuronal energy source. J. Neurosci., 2011, 31, (20), 7477-7485.